We are live on ! Find out more
ES

Enavate Sciences Portfolio holdings

AUM $352M
1-Year Est. Return 220.14%
This Fund
S&P 500
This Quarter Est. Return
+70.3%
1 Year Est. Return
+220.14%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$328M
AUM Growth
+$151M
Cap. Flow
+$27.4M
Cap. Flow %
8.36%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BBOT
BridgeBio Oncology
BBOT
+$27.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBIO
1
Zenas BioPharma
ZBIO
$1.98B
$83.5M 25.5%
3,761,359
– –
SION
2
Sionna Therapeutics
SION
$2.13B
$72.9M 22.25%
2,478,030
– –
IMNM icon
3
Immunome
IMNM
$2.58B
$55.8M 17.05%
4,768,583
– –
UPB
4
Upstream Bio Inc
UPB
$343M
$46.3M 14.13%
2,459,703
– –
BBOT
5
BridgeBio Oncology
BBOT
$648M
$30.4M 9.29%
+2,626,946
New +$27.4M
CMPX icon
6
Compass Therapeutics
CMPX
$344M
$27.3M 8.32%
7,788,150
– –
CAMP icon
7
CAMP4 Therapeutics
CAMP
$179M
$11.4M 3.47%
3,785,802
– –

Similar funds

HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
FFO
Fiduciary Family Office Boca Raton, Florida $351M AUM 22.19% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
SMC
Spider Management Company Richmond, Virginia $351M AUM 18.35% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Enavate Sciences's Q3 2025 Portfolio in Review

As of Q3 2025, Enavate Sciences held 7 positions worth $328M, up 86% from $177M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Enavate Sciences deployed $27.4M of net new capital in Q3 2025, opening 1 new position. Its largest new stake was BridgeBio Oncology: 2,626,946 shares worth $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Enavate Sciences's largest Q3 2025 buy was BridgeBio Oncology: 2,626,946 shares worth $30.4M.
  • Enavate Sciences's ten largest holdings make up 100% of its $328M portfolio in Q3 2025.
  • Enavate Sciences opened 1 new position and closed 0 in Q3 2025.
  • Enavate Sciences's portfolio value rose 86% quarter-over-quarter to $328M.

Based on Enavate Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.